This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to
see how well they work with or without high or low-dose radiation therapy in treating
patients with colorectal or non-small cell lung cancer that has spread to other parts of the
body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the
ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill
tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may
work better in treating patients with colorectal or non-small cell lung cancer.